276 related articles for article (PubMed ID: 29920929)
1. Hereditary angioedema: the plasma contact system out of control.
De Maat S; Hofman ZLM; Maas C
J Thromb Haemost; 2018 Sep; 16(9):1674-1685. PubMed ID: 29920929
[TBL] [Abstract][Full Text] [Related]
2. Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway.
Kaplan AP; Joseph K
Adv Immunol; 2014; 121():41-89. PubMed ID: 24388213
[TBL] [Abstract][Full Text] [Related]
3. Factor XII-independent activation of the bradykinin-forming cascade: Implications for the pathogenesis of hereditary angioedema types I and II.
Joseph K; Tholanikunnel BG; Bygum A; Ghebrehiwet B; Kaplan AP
J Allergy Clin Immunol; 2013 Aug; 132(2):470-5. PubMed ID: 23672780
[TBL] [Abstract][Full Text] [Related]
4. Treatment of episodes of hereditary angioedema with C1 inhibitor: serial assessment of observed abnormalities of the plasma bradykinin-forming pathway and fibrinolysis.
Joseph K; Tholanikunnel TE; Kaplan AP
Ann Allergy Asthma Immunol; 2010 Jan; 104(1):50-4. PubMed ID: 20143645
[TBL] [Abstract][Full Text] [Related]
5. Biochemistry, molecular genetics, and clinical aspects of hereditary angioedema with and without C1 inhibitor deficiency.
Miyata T; Horiuchi T
Allergol Int; 2023 Jul; 72(3):375-384. PubMed ID: 37169642
[TBL] [Abstract][Full Text] [Related]
6. C1-inhibitor polymers activate the FXII-dependent kallikrein-kinin system: Implication for a role in hereditary angioedema.
Madsen DE; Sidelmann JJ; Biltoft D; Gram J; Hansen S
Biochim Biophys Acta; 2015 Jun; 1850(6):1336-42. PubMed ID: 25800206
[TBL] [Abstract][Full Text] [Related]
7. A novel assay to diagnose hereditary angioedema utilizing inhibition of bradykinin-forming enzymes.
Joseph K; Bains S; Tholanikunnel BG; Bygum A; Aabom A; Koch C; Farkas H; Varga L; Ghebrehiwet B; Kaplan AP
Allergy; 2015 Jan; 70(1):115-9. PubMed ID: 25186184
[TBL] [Abstract][Full Text] [Related]
8. High-molecular-weight kininogen cleavage correlates with disease states in the bradykinin-mediated angioedema due to hereditary C1-inhibitor deficiency.
Suffritti C; Zanichelli A; Maggioni L; Bonanni E; Cugno M; Cicardi M
Clin Exp Allergy; 2014 Dec; 44(12):1503-14. PubMed ID: 24552232
[TBL] [Abstract][Full Text] [Related]
9. Factor VII activating protease (FSAP) is not essential in the pathophysiology of angioedema in patients with C1 inhibitor deficiency.
Gramstad OR; Kandanur SPS; Etscheid M; Nielsen EW; Kanse SM
Mol Immunol; 2022 Feb; 142():95-104. PubMed ID: 34973499
[TBL] [Abstract][Full Text] [Related]
10. Hereditary and acquired C1-inhibitor-dependent angioedema: from pathophysiology to treatment.
Zeerleder S; Levi M
Ann Med; 2016; 48(4):256-67. PubMed ID: 27018196
[TBL] [Abstract][Full Text] [Related]
11. Hereditary angioedema: Pathophysiology (HAE type I, HAE type II, and HAE nC1-INH).
Wedner HJ
Allergy Asthma Proc; 2020 Nov; 41(Suppl 1):S14-S17. PubMed ID: 33109319
[TBL] [Abstract][Full Text] [Related]
12. Hereditary angioedema: a current state-of-the-art review, III: mechanisms of hereditary angioedema.
Davis AE
Ann Allergy Asthma Immunol; 2008 Jan; 100(1 Suppl 2):S7-12. PubMed ID: 18220146
[TBL] [Abstract][Full Text] [Related]
13. Complement, Kinins, and Hereditary Angioedema: Mechanisms of Plasma Instability when C1 Inhibitor is Absent.
Kaplan AP; Joseph K
Clin Rev Allergy Immunol; 2016 Oct; 51(2):207-15. PubMed ID: 27273087
[TBL] [Abstract][Full Text] [Related]
14. sgp120 and the contact system in hereditary angioedema: A diagnostic tool in HAE with normal C1 inhibitor.
Larrauri B; Hester CG; Jiang H; Miletic VD; Malbran A; Bork K; Kaplan A; Frank M
Mol Immunol; 2020 Mar; 119():27-34. PubMed ID: 31955064
[TBL] [Abstract][Full Text] [Related]
15. Patterns of C1-Inhibitor/Plasma Serine Protease Complexes in Healthy Humans and in Hereditary Angioedema Patients.
Kajdácsi E; Jandrasics Z; Veszeli N; Makó V; Koncz A; Gulyás D; Köhalmi KV; Temesszentandrási G; Cervenak L; Gál P; Dobó J; de Maat S; Maas C; Farkas H; Varga L
Front Immunol; 2020; 11():794. PubMed ID: 32431708
[TBL] [Abstract][Full Text] [Related]
16. A Decade of Change: Recent Developments in Pharmacotherapy of Hereditary Angioedema (HAE).
Bork K
Clin Rev Allergy Immunol; 2016 Oct; 51(2):183-92. PubMed ID: 27207174
[TBL] [Abstract][Full Text] [Related]
17. Bradykinin-mediated diseases.
Kaplan AP
Chem Immunol Allergy; 2014; 100():140-7. PubMed ID: 24925394
[TBL] [Abstract][Full Text] [Related]
18. Analysis of cold activation of the contact system in hereditary angioedema with normal C1 inhibitor.
Larrauri B; Hester CG; Jiang H; Miletic VD; Malbran A; Bork K; Kaplan A; Frank M
Mol Immunol; 2021 Aug; 136():150-160. PubMed ID: 34153620
[TBL] [Abstract][Full Text] [Related]
19. Deficiency of plasminogen activator inhibitor 2 in plasma of patients with hereditary angioedema with normal C1 inhibitor levels.
Joseph K; Tholanikunnel BG; Wolf B; Bork K; Kaplan AP
J Allergy Clin Immunol; 2016 Jun; 137(6):1822-1829.e1. PubMed ID: 26395818
[TBL] [Abstract][Full Text] [Related]
20. Impaired control of the contact system in hereditary angioedema with normal C1-inhibitor.
Bova M; Suffritti C; Bafunno V; Loffredo S; Cordisco G; Del Giacco S; De Pasquale TMA; Firinu D; Margaglione M; Montinaro V; Petraroli A; Radice A; Brussino L; Zanichelli A; Zoli A; Cicardi M
Allergy; 2020 Jun; 75(6):1394-1403. PubMed ID: 31860755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
